Markets

Prologis, Inc. announced it will fully redeem its 3.00% notes due June 2 2026 (CUSIP 74340XBB6) at 102.1% of principal on January 9 2026, removing the bonds from the NYSE. The early buy‑back locks in a lower cost of capital as market rates exceed 4%, strengthens the balance sheet, and may boost its credit rating. Saved cash will support Prologis Labs’ AI and IoT upgrades for smarter warehousing. Analysts view the modest premium as a bullish sign, though risks remain from global economic headwinds, freight‑rate volatility, and currency exposure.

words.Dyne Therapeutics (Nasdaq: DYN) will release top‑line results from the Registrational Expansion Cohort of its Phase 1/2 DELIVER trial for zeleciment rostudirsen (DYNE‑251) on December 8 2025 at 8:00 a.m. ET via an investor webcast, with a press release beforehand and a 90‑day replay. The stock closed at $20.28, trading above its 200‑day moving average and showing modestly elevated volume. Historical patterns suggest clinical milestones can trigger sharp short‑term price swings.

.Rigel’s Phase 1b trial of oral R289, a dual IRAK1/4 inhibitor, in relapsed/refractory lower‑risk MDS showed good tolerability and preliminary efficacy. In patients ≥ 75 years with a median of three prior therapies, 33 % (6/18) of transfusion‑dependent subjects receiving ≥ 500 mg daily achieved durable red‑blood‑cell transfusion independence, with responders showing 2.9–6.1 g/dL hemoglobin gains. Common adverse events were mild GI symptoms and fatigue; grade 3/4 events included anemia and neutropenia. R289 met target plasma levels and holds FDA orphan‑drug and Fast Track designations.

.Molecular Partners (NASDAQ:MOLN) presented updated Phase 1/2a data for its tetra‑specific T‑cell engager MP0533 in relapsed/refractory AML at ASH 2025. Of 54 patients treated, 8 of 48 evaluable patients responded, including five composite complete responses and three morphologic leukemia‑free states. Densified, higher‑frequency dosing (cohorts 8‑9) was well tolerated and yielded markedly higher serum exposure, with responses concentrated in patients whose baseline marrow blasts were below 20 %. One cohort‑8 patient remains in remission for over a year; cohort 10 results are expected in 2026.

Onco‑Innovations announced it has hired a U.S. investment bank to advise on a possible Nasdaq cross‑listing and assess a concurrent equity financing. The advisory will evaluate listing requirements, regulatory and governance issues, and capital‑raising strategies. While the engagement signals interest in U.S. market access and additional capital, the company cautions that neither a listing nor financing is guaranteed and details remain under discussion.

Zai Lab announced that VYVGART, NUZYRA and ZEJULA have been renewed on China’s 2025 NRDL, expanding access for generalized myasthenia gravis, community‑acquired pneumonia/ABSSSI, and maintenance therapy in platinum‑sensitive ovarian cancer. The renewals underscore clinical value, lower patient costs, and position Zai Lab for growth in immunology, infectious disease and oncology, with projected multi‑year revenue uplift and an 18‑22% CAGR through 2028.

The University of Wisconsin captured the Abbott‑Big Ten “We Give Blood” title, earning a $1 million grant to fund health initiatives. The drive saw a 319% jump in participation, with 83,043 donations—roughly 250,000 lives saved—across the conference. Student donors increased 168% from 2024, and 37% were first‑time donors; 92% say they will donate again. Competitive “One‑Up” challenges and campus engagement spurred the surge, underscoring the power of sport‑driven philanthropy to address the nation’s severe blood shortage.

BioNTech and OncoC4 presented non‑pivotal Phase 3 PRESERVE‑003 data for the selective T‑reg modulator gotistobart (BNT316/ONC‑392) in previously treated metastatic squamous NSCLC. With 45 patients on gotistobart and 42 on docetaxel, median overall survival was not reached versus 10 months, and 12‑month OS rates were 63.1 % versus 30.3 %. The hazard ratio for death was 0.46 (95 % CI 0.25–0.84; p = 0.0102). Grade ≥ 3 treatment‑related adverse events occurred in 42.2 % of gotistobart patients. The drug holds FDA Fast Track status.

Arcellx reported Phase 2 iMMagine‑1 results for its CAR‑T therapy anito‑cel in relapsed/refractory multiple myeloma. Among 117 patients, the overall response rate reached 96% with 74% achieving complete or stringent complete responses; 95% of evaluable patients attained MRD negativity, 83% sustaining it >6 months. Twelve‑month progression‑free and overall survival were 82.1% and 94.0%, respectively, with median PFS/OS not yet reached. Safety was favorable, showing no delayed neurotoxicities. The company reaffirmed a 2026 U.S. launch in partnership with Kite, aiming for broader global rollout.

Prelude Therapeutics disclosed preclinical data at ASH 2025 on two MPN programs: PRT12396, a JAK2V617F‑selective JH2 inhibitor that outperforms ruxolitinib, has completed GLP toxicology and is slated for IND filing and Phase 1 in Q1 2026 under an exclusive Incyte option; and mutant CALR‑directed degrader antibody conjugates delivering a CDK9 degrader, which achieve deep, mutant‑selective cell killing in vitro and in vivo while sparing normal hematopoietic cells. Both remain preclinical.